InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 32.03% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 28.99% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -49.94% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -41.05% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -62.71% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -205.66% |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 36.11% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -59.10% |
| 10 | InMed Pharmaceuticals | 5.94 Mn | 696,491.41 | - | 7.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.49% |
| Dec 31, 2025 | -42.82% |
| Sep 30, 2025 | -36.62% |
| Jun 30, 2025 | 184.23% |
| Mar 31, 2025 | 30.73% |
| Dec 31, 2024 | 18.95% |
| Sep 30, 2024 | -28.54% |
| Jun 30, 2024 | 21.03% |
| Mar 31, 2024 | -50.56% |
| Dec 31, 2023 | -33.11% |
| Sep 30, 2023 | -14.82% |
| Jun 30, 2023 | 20.91% |
| Mar 31, 2023 | -6.51% |
| Dec 31, 2022 | 48.56% |
| Sep 30, 2022 | 32.04% |